However, ASOs that target TDP-43 have not yet been investigated for their possible therapeutic use23 and, therefore, the therapeutic potential of the TDP-43-lowering approach using ASOs remains unknown despite the central roles of TDP-43 in the pathogenesis of ALS/FTD.24 Here, TARDBP is linked to amyotrophic lateral sclerosis.